In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-I and are capable of inhibiting the interaction of PD-I with PD-LI. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
[EN] AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF<br/>[FR] COMPOSÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE HPK1 ET LEUR UTILISATION
申请人:BEIGENE LTD
公开号:WO2021032148A1
公开(公告)日:2021-02-25
Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
[EN] BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE<br/>[FR] COMPOSÉS BICYCLIQUES INDOLE-PYRIMIDINE INHIBITEURS DE PI3K SÉLECTIFS POUR P110 DELTA ET LEURS PROCÉDÉS D'UTILISATION
申请人:HOFFMANN LA ROCHE
公开号:WO2010136491A1
公开(公告)日:2010-12-02
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PBK, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Formula I(Ia和Ib)化合物,其中(i)X1为N且X2为S,(ii)X1为CR7且X2为S,(iii)X1为N且X2为NR2,(iv)X1为CR7且X2为O,或(v)X1为CR7且X2为NR2,包括立体异构体、互变异构体、代谢物及其药学上可接受的盐,用于抑制PBK的δ同工酶,并用于治疗由脂质激酶介导的疾病,如炎症、免疫和癌症。公开了使用Formula I化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这些疾病,或相关病理条件的方法。
A Strategy for Synthesizing Axially Chiral Naphthyl‐Indoles: Catalytic Asymmetric Addition Reactions of Racemic Substrates
作者:Fei Jiang、Ke‐Wei Chen、Ping Wu、Yu‐Chen Zhang、Yinchun Jiao、Feng Shi
DOI:10.1002/anie.201908279
日期:2019.10.14
A newstrategy for enantioselective synthesis of axially chiral naphthyl-indoles has been established through catalytic asymmetric addition reactions of racemic naphthyl-indoles with bulky electrophiles. Under chiral phosphoric acid catalysis, azodicarboxylates and o-hydroxybenzyl alcohols served as bulky but reactive electrophiles that were attacked by C2-unsubstituted naphthyl-indoles, which underwent
An economical and scalable electrochemical protocol for regioselective 3C–H halogenation of indole derivatives is reported. This strategy provides access to a host of 3‐iodo‐, 3‐bromo‐, 3‐chloro‐, and 3‐thiocyanoindole derivatives under mild conditions using inexpensive (pseudo)halide salts as the sole reagent. No supplementary electrolyte salt is necessary.
The usefulness of 3-iodoindoles available for introduction of an indole unit is presented. The reaction of various halo-3-iodoindoles with 1,4-naphthoquinone gave the corresponding 2-(3-indolyl)-1-4,naphthoquinones in moderate yields. The 3-iodoindole was used for synthesis of a compound containing both naph-thazarin and indole skeletons.